Sunil Samnani, Rishad Khan, Steven J. Heitman, Robert J. Hilsden, Michael F. Byrne, Samir C. Grover & Nauzer Forbes

Screening-related colonoscopy is a vital component of screening initiatives to both diagnose and prevent colorectal cancer (CRC), with prevention being reliant upon early and accurate detection of pre-malignant lesions. Several strategies, techniques, and interventions exist to optimize endoscopists’ adenoma detection rates (ADR).

“Hot off the press” paper on ways to improve adenoma detection in colonoscopy. I contributed the AI section. Thanks to senior author, Nauzer Forbes, and co-authors, Sunil Samnani, Rishad Khan, Steven Heitman, Robert Hilsden, and Samir C. Grover.

Dr. Michael Byrne
CEO & Founder
Satisfai Health 

Optimizing adenoma detection in screening-related colonoscopy

Date:  Published Online 10 May 2023


Artificial intelligence represents a new era within the field of gastroenterology, and the amount of research surrounding artificial intelligence in patients with inflammatory bowel disease is on the rise. 

Satisfai Health CEO & Founder Dr. Michael Byrne shares, “Further to our recent paper on AI in Clinical Trials for IBD, another review from our group has just been published on how Artificial Intelligence solutions are coming for the management of Inflammatory Bowel Disease in Clinical Practice and Future Directions.”

The purpose of this review is to provide an overview of the unmet needs in the management of inflammatory bowel disease in clinical practice and how artificial intelligence tools can address these gaps to transform patient care.

Artificial intelligence in inflammatory bowel disease

Date:  Published Online 20 April 2023


In this review, state-of-the-art endoscopic assessment of mucosal disease activity in inflammatory bowel disease clinical trials is described, covering the potential for artificial intelligence to transform the current paradigm, its limitations, and suggested next steps.

“Artificial Intelligence solutions will change how clinical trials are conducted….for the better! Our review in Journal of Crohn’s and Colitis, jjad029 describes this opportunity in the field of inflammatory bowel disease.”

Dr. Michael Byrne
CEO &Founder
SatisFai Health

Artificial Intelligence in Inflammatory Bowel Disease Endoscopy

Date:  Published, 22 February 2023

AI in Clinical Medicine: A Practical Guide for Healthcare Professionals

Satisfai Health is delighted to announce that our textbook “AI in Clinical Medicine” is being released.  Our CEO, Dr. Michael Byrne, toiled with a capable team to deliver an invaluable reference aimed at getting the medical community up to speed on AI and its application to Clinical Medicine. 

AI in Clinical Medicine: A Practical Guide for Healthcare Professionals is the definitive reference book for the emerging and exciting use of AI throughout clinical medicine. AI in Clinical Medicine: A Practical Guide for Healthcare Professionals is divided into four sections. Section 1 provides readers with the basic vocabulary that they require, a framework for AI, and highlights the importance of robust AI training for physicians. Section 2 reviews foundational ideas and concepts, including the history of AI. Section 3 explores how AI is applied to specific disciplines. Section 4 describes emerging trends, and applications of AI in medicine in the future.

Date:  Published, February 2023

AI in IBD: Implications for Clinical Trials

Date:  Published, February 2023


Satisfai Health is pleased to announce our latest paper describing how AI will ultimately transform the clinical trials paradigm, certainly for Inflammatory Bowel Disease.  

Yuichi Mori, James E. East, Cesare Hassan, Natalie Halvorsen, Tyler M. Berzin, Michael Byrne, Daniel von Renteln, David G. Hewett, Alessandro Repici, Mohan Ramchandani, Maryam Al Khatry, Shin-ei Kudo, Pu Wang, Honggang Yu, Yutaka Saito, Masashi Misawa, Sravanthi Parasa, Carolina Ogawa Matsubayashi, Haruhiko Ogata, Hisao Tajiri, Nonthalee Pausawasdi, Evelien Dekker, Omer F. Ahmad, Prateek Sharma, Douglas K. Rex

The number of artificial intelligence (AI) tools for colonoscopy on the market is increasing with supporting clinical evidence. Nevertheless, their implementation is not going smoothly for a variety of reasons, including lack of data on clinical benefits and cost-effectiveness, lack of trustworthy guidelines, uncertain indications, and cost for implementation.

To address this issue and better guide practitioners, the World Endoscopy Organization (WEO) has provided its perspective about the status of AI in colonoscopy as the position statement.

“Our physician group at the World Endoscopy Organization (WEO) released this position statement on the challenges (and solutions!) to the implementation of AI into colonoscopy practice. Worth a read!”

Dr. Michael Byrne
CEO & Founder
Satisfai Health 

implementation of artificial intelligence in colonoscopy

Date:  Published Online 7 February 2023

Editorial: Artificial Intelligence–Aided Colonoscopy for Characterizing and Detecting Colorectal Polyps: Required, Nice to Have, or Overhyped?

Michael F. Byrne, Daniel Von Renteln, Alan N. Barkun


Satisfai Health is pleased to present our editorial in GASTROENTEROLOGY on the rapidly evolving field of AI in colon cancer screening.


Date:  Published, January 2023

Move Over, Colon. It’s Time for the Esophagus to Take Center Stage for Artificial Intelligence and Computer-Aided Detection of Barrett’s!

Date:  Published, June 2021

Practical Deep Learning Tool for Scoring of Ulcerative Colitis Disease Activity in Central Reading


Date:  Published, June 2021

Artificial Intelligence (AI) in Endoscopy – Deep Learning for Scoring of Ulcerative Colitis Disease Activity Under Multiple Scoring Systems.


Date:  Published, May 27 2021


Request a Demo

Dr. Reno Panaccione

Director of IBD

Dr. Panaccione is currently a Professor of Medicine, the Director of the Inflammatory Bowel Disease Clinic at the University of Calgary and Director of Gastroenterology Research.

Dr. Panaccione graduated from the University of Western Ontario (London, Ontario) with a degree in Medicine in 1993. He went on to complete his Internal Medicine and Gastroenterology training at the University of Western Ontario and is certified as a fellow of the Royal College of Physicians and Surgeons of Canada in both Internal Medicine and Gastroenterology. Dr. Panaccione completed advanced training in Inflammatory Bowel Disease at the Mayo Clinic in Rochester, Minnesota. He joined the faculty of Medicine at the University of Calgary in 1999. He is an internationally recognized expert in inflammatory bowel disease. He has lectured nationally and internationally on various topics in inflammatory bowel disease and has delivered over 200 lectures in the last five years.

He is the author of many peer-reviewed articles (~250) and book chapters (25) on inflammatory bowel disease. His special interest lies in the fields of advanced therapies, biological therapy, and delivery of care through the implementation of clinical trials. He is a recognized authority on the use of biologics and has co-authored numerous guidelines on the management of inflammatory bowel disease for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn’s disease and ulcerative colitis. He has published in and reviews for prestigious journals including NEJM, Lancet, Gastroenterology and Gut. He sits on the editorial board of Inflammatory Bowel Diseases, JCC, APT, and the Canadian Journal of Gastroenterology.

He is presently the medical director for the Crohn’s and Colitis Canada (CCC) Calgary Chapter and sits on the Medical Advisory council for the Crohn’s and Colitis Foundation of Canada. He is the national chair of the CCC scholarship program. He has been awarded the highest honour, the Finkelstein award by Crohn’s and Colitis Canada for his work in the field of IBD. He is also an elected member of the International Organization of Inflammatory Bowel Disease (IOIBD) reflecting his status in the area. He was awarded the CAG Visiting Professor Award in 2016 for his contribution o the field of Gastroenterology in Canada. He is ranked amongst the top ten experts in the field worldwide ( He presently holds a senior leadership position within Alberta Health Services as the Medical Lead for Systems Integration with the mandate of improving the efficiency and quality of care that is delivered to patients.

Dr. Douglas Rex

Director of Colorectal Cancer

Dr. Douglas K. Rex is Distinguished Professor of Medicine at Indiana University School of Medicine, Chancellor’s Professor at Indiana University Purdue University Indianapolis, and Director of Endoscopy at Indiana University Hospital in Indianapolis. He graduated from Harvard College, Summa Cum Laude in 1976 and with highest distinction from Indiana University School of Medicine in 1980. He served as Chief Medical Resident at Indiana University Hospital and joined the faculty at Indiana University in 1985. He received the Outstanding Teacher Award in the Introduction to Medicine course five times and has been awarded the Indiana University School of Medicine Outstanding Teacher Award as well as Department of Medicine’s Excellence in Teaching Award. He is a full-time clinical gastroenterologist at Indiana University Hospital.

His major research interests have been in colorectal disease and, in particular, colorectal cancer screening and the technical performance of colonoscopy. He co-authored the colorectal cancer screening recommendations of the American College of Gastroenterology and the U.S. Multi-Society Task Force on Colorectal Cancer. He also authored the recommendations on quality in colonoscopy of the U.S. Multi-Society Task Force on Colorectal Cancer and the American College of Gastroenterology/American Society of Gastrointestinal Endoscopy. He has authored more than 200 original research papers, 55 book chapters, 200 invited papers, 40 editorials, and 40 guideline papers. He is an Associate Editor of Journal Watch Gastroenterology and serves on the editorial boards of 11 gastroenterology journals.

He is the current chair of the U.S. Multi-Society (ACG, ASGE, AGA, ACP-ASIM) Task Force on Colorectal Cancer. He has also served in the American College of Gastroenterology as Chairman of the Board of Governors and is a Past President of the ACG. He is a member of the Governing Board of ASGE and a recipient of the Rudolph V. Schindler Award from ASGE.

Dr. Michael Byrne

CEO & Founder

Dr. Michael Byrne provides senior leadership and clinical expertise to Satisfai Health and is a clinical innovator with over 20 years experience as a practicing physician. He is the founder of both Satisfai Health and its ai4gi joint venture. He is a Clinical Professor of Medicine in the Division of Gastroenterology at Vancouver General Hospital and UBC. He is also director of the Interventional Endoscopy Fellowship at VGH, and is the former Director of Endoscopy at VGH/UBC.

He has worked in the medical device space for several years. Prior to his role with Satisfai Health and his participation in the ai4gi project, he has worked with the Biotechnology Industry in several areas including colon cancer genetic testing, and novel applications of Photodynamic therapy for Gastrointestinal disease.

He is a graduate of Cambridge and Liverpool Universities. He has a strong research background in both basic science and clinical medicine with hands-on training in molecular sciene and pharmacology. He received an MD by thesis from the University of Cambridge for his work on Helicobacter Pylori and Cyclooxygenase. He also has a long track record of clinical research. Dr. Byrne has published extensively with over 90 peer reviewed publications and over 100 abstract presentations at National and International Meetings.

After several years working in the UK and Ireland, Dr. Byrne completed an Interventional Endoscopy Fellowship as well as working as an attending physician at Duke University Medical Center, North Carolina. He moved to his current role in Vancouver in 2003.

His main clinical interests are in the field of ERCP, interventional endoscopy, optical biopsy, colon cancer, pancreaticobiliary disease, and IBD.